Central Oregon Medical Society
Join COMS now!
coms@comedsoc.org


  • Home
  • Login
  • About Us
    • About Us
    • Executive Committee
  • Members
  • Events
    • Event Schedule
    • Past Events
  • News
    • COMS News
    • Firearm Prevalence & Deaths
    • Opioid Pandemic
    • Opioid Deaths & Marijuana
    • Sports Medicine
    • Climate Change
  • Resources
    • St. Charles Grand Rounds
    • Marijuana Issues
    • Breast Cancer Screening
    • Suicide in Oregon
    • Suicides Homicides Gun Control
    • Suicides Homicides Against Con
    • Adolescent & Young Adult
  • Wellness
    • * COMS Wellness Program *
    • *** Crisis (24/7) Lines ***
    • Caduceus Recovery Group
    • Medscape 2019 Survey
    • Health Professional Wellness
    • Proposed Physician Burnout Fix
    • J Med Regulation Special Issue
    • Medical License Applications
    • Twitter Capsules of Gratitude
    • Suffering from Moral Injury
    • Stable, Don't Touch Nothing
    • SCHC Inner Resiliency Course
  • Contact
Back to Nation's Manmade Opioid Epidemic
07May 2017 BY

Opioid Providers Spent $880M to Lobby Lawmakers to Stop Regs on their Drugs

img

  • Over the past decade, opioid producers and suppliers have spent more than $880 million at the federal and state level lobbying lawmakers to stop new regulations on their drugs, while calling on policymakers to actually loosen access to painkillers. That’s eight times as much as the gun lobby spent on its causes, according to Mother Jones.
  • ... it often worked: In Maine, for example, drugmakers successfully pushed for a bill that required insurers to cover opioid painkillers that are supposedly harder to abuse.
  • In fact, the DEA admits that pharmaceutical companies played a key role in its decision making in its own statements. Here is the agency in 1999 after an unnamed company asked for a formal hearing about the quotas: “In addition, one company requested a hearing to address the aggregate production quota for oxycodone (for sale) or hydromorphone if the aggregate production quotas were not increased sufficiently. The DA [sic], based on the date [sic] provided, has increased the aggregate production quotas for both oxycodone (for sale) and hydromorphone and has determined that a hearing is not necessary.”
  • The company didn’t even have hold a formal hearing to get what it wanted from the DEA.
  • All of this should make it clear: Regulation failed.

Click here for the full report

Join COMS now!



Email: coms@comedsoc.org


Website Designed by James Web Design LLC. • All Right Reserved © Central Oregon Medical Society  

Login

...

Password Reset Request Received

You will receive an email shortly that contains a link to restore your access to the site. Once you follow the link in the mail, you will then be prompted to reset your password.

Reset Password?

Your Member Email